Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 5
2005 5
2006 7
2007 2
2008 2
2009 7
2010 3
2011 3
2012 7
2013 1
2014 6
2015 3
2016 7
2017 3
2018 8
2019 7
2020 8
2021 5
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy of melanoma.
Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M. Parmiani G, et al. Among authors: anichini a. Semin Cancer Biol. 2003 Dec;13(6):391-400. doi: 10.1016/j.semcancer.2003.09.001. Semin Cancer Biol. 2003. PMID: 15001157 Review.
Heme catabolism by tumor-associated macrophages controls metastasis formation.
Consonni FM, Bleve A, Totaro MG, Storto M, Kunderfranco P, Termanini A, Pasqualini F, Alì C, Pandolfo C, Sgambelluri F, Grazia G, Santinami M, Maurichi A, Milione M, Erreni M, Doni A, Fabbri M, Gribaldo L, Rulli E, Soares MP, Torri V, Mortarini R, Anichini A, Sica A. Consonni FM, et al. Among authors: anichini a. Nat Immunol. 2021 May;22(5):595-606. doi: 10.1038/s41590-021-00921-5. Epub 2021 Apr 26. Nat Immunol. 2021. PMID: 33903766
Immunotherapy for brain metastases and primary brain tumors.
Di Giacomo AM, Mair MJ, Ceccarelli M, Anichini A, Ibrahim R, Weller M, Lahn M, Eggermont AMM, Fox B, Maio M. Di Giacomo AM, et al. Among authors: anichini a. Eur J Cancer. 2023 Jan;179:113-120. doi: 10.1016/j.ejca.2022.11.012. Epub 2022 Nov 24. Eur J Cancer. 2023. PMID: 36521332
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Noviello TMR, et al. Among authors: anichini a. Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4. Nat Commun. 2023. PMID: 37739939 Free PMC article. Clinical Trial.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. Lo Russo G, et al. Among authors: anichini a. J Immunother Cancer. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. J Immunother Cancer. 2023. PMID: 37286305 Free PMC article. Clinical Trial.
Reply to E. Hindié.
Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. Maurichi A, et al. Among authors: anichini a. J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701413 Free PMC article. No abstract available.
Immune Escape Mechanisms in Non Small Cell Lung Cancer.
Anichini A, Perotti VE, Sgambelluri F, Mortarini R. Anichini A, et al. Cancers (Basel). 2020 Dec 2;12(12):3605. doi: 10.3390/cancers12123605. Cancers (Basel). 2020. PMID: 33276569 Free PMC article. Review.
APAF-1 signaling in human melanoma.
Anichini A, Mortarini R, Sensi M, Zanon M. Anichini A, et al. Cancer Lett. 2006 Jul 18;238(2):168-79. doi: 10.1016/j.canlet.2005.06.034. Epub 2005 Aug 10. Cancer Lett. 2006. PMID: 16095810 Review.
Interleukin-12: biological properties and clinical application.
Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Del Vecchio M, et al. Among authors: anichini a. Clin Cancer Res. 2007 Aug 15;13(16):4677-85. doi: 10.1158/1078-0432.CCR-07-0776. Clin Cancer Res. 2007. PMID: 17699845 Review.
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A, Molla A, Nicolini G, Perotti VE, Sgambelluri F, Covre A, Fazio C, Lofiego MF, Di Giacomo AM, Coral S, Manca A, Sini MC, Pisano M, Noviello T, Caruso F, Brich S, Pruneri G, Maurichi A, Santinami M, Ceccarelli M, Palmieri G, Maio M, Mortarini R; EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators. Anichini A, et al. J Exp Clin Cancer Res. 2022 Nov 17;41(1):325. doi: 10.1186/s13046-022-02529-5. J Exp Clin Cancer Res. 2022. PMID: 36397155 Free PMC article.
99 results